Has Monika Dhillon, MD received payments from drug or device companies?

Yes. Drug and device makers reported $131,314 in general payments to Monika Dhillon, MD across 995 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Monika Dhillon, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Monika Dhillon, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Monika Dhillon, MD

Nephrology · Baltimore, MDNPI 1487632600

Payments from drug & device makers

$131,314in general payments, 2019–2025

Across 995 payments — averaging $131.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$70K
AstraZeneca$38K
Akebia Therapeutics Inc$6K
Kowa Pharmaceuticals America, Inc.$2K
Novo Nordisk$2K
Bayer$2K
plus $11K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	241	$70,363
AstraZeneca(2 entities)	162	$38,440
Akebia Therapeutics Inc	53	$5,987
Kowa Pharmaceuticals America, Inc.	44	$2,009
Novo Nordisk	59	$1,771
Bayer	42	$1,535
Mallinckrodt Hospital Products Inc.	41	$1,240
Viiv Healthcare Company	43	$1,114
Novartis	25	$1,055
AbbVie(2 entities)	22	$752
Dexcom, Inc.	8	$724
Vifor Pharma, Inc.	18	$495
ANI Pharmaceuticals, Inc.	17	$466
Sanofi-aventis U.S. LLC	6	$416
Otsuka America Pharmaceutical, Inc.	19	$356
Johnson & Johnson	13	$350
Calliditas Therapeutics US Inc.	14	$276
Fresenius USA Marketing, Inc.	13	$248
Sumitomo Pharma America, Inc.	12	$245
Travere Therapeutics, Inc.	24	$231
Boehringer Ingelheim	5	$222
Pfizer	8	$201
Protega Pharmaceutials Inc	2	$185
Amarin Pharma, Inc.	8	$184
Cequr Corporation	2	$162
Exact Sciences	4	$155
Esperion Therapeutics, Inc.	9	$155
Idorsia Pharmaceuticals US Inc	2	$149
Lilly USA, LLC	8	$135
Globus Medical	1	$124
BETA Bionics, Inc.	1	$114
Phadia US Inc.	2	$107
Merck	5	$101
Corcept Therapeutics	5	$100
GSK	5	$96
Astellas Pharma US Inc	4	$93
Sunovion Pharmaceuticals Inc.	4	$83
Ironwood Pharmaceuticals, Inc	5	$74
Mylan Specialty L.p.	1	$74
Lexicon Pharmaceuticals, Inc.	4	$71
Tactile Systems Technology Inc	1	$70
Ultragenyx Pharmaceutical Inc.	3	$56
Daiichi Sankyo Inc.	3	$54
Paratek Pharmaceuticals, Inc.	2	$46
Eisai Inc.	2	$43
Collegium Pharmaceutical, Inc.	2	$40
Biohaven Pharmaceutical Holding Company Ltd.	2	$39
E.r. Squibb & Sons, L.L.C.	2	$34
Verona Pharma, Inc.	2	$33
Cashflow Solutions, LLC	2	$33
Alk-abello, Inc	2	$30
Sanofi Pasteur Inc.	2	$29
Valeritas, Inc.	1	$22
Scpharmaceuticals Inc.	1	$21
Hikma Pharmaceuticals USA	1	$19
OPKO Pharmaceuticals, LLC	1	$17
Zealand Pharma US, Inc.	1	$16
TMS Neurohealth Centers Inc.	1	$15
Gilead	1	$14
Ardelyx, Inc.	1	$14

How this compares

$131,314 in reported general payments places this provider in the 90th percentile of 285 nephrology providers in Maryland.

See all nephrology providers in Maryland →

Medicare billing

Part B allowed, 2024

$191,334

Medicare patients

286

Services billed

1,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in Baltimore

Christopher SperatiBaltimore$1.5M
Michelle EstrellaBaltimore$1.2M
Mohamed AttaBaltimore$1.1M
Chirag ParikhBaltimore$1M
Matthew WeirBaltimore$518K
Duvuru GeethaBaltimore$409K
Preeti ChandraBaltimore$287K
Morgan GramsBaltimore$260K
Mohamad HanounehBaltimore$174K
Stephen SeligerBaltimore$134K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →